News

Home / News and Events

March 25, 2025 | Featured

Intract Announces Positive Preclinical Results for its Oral Anti-TNFα Antibody Program

November 12, 2024 | Featured

Intract Announces Appointment of Srini Ramanathan, PhD, Chief Development Officer at Roivant Sciences as a Key Product Development Advisor

September 30, 2024 | Uncategorised

Intract Signs Nonbinding Letter of Intent to Merge with Tharimmune to Create Transformative Oral Biologic Therapeutics Company

September 16, 2024 | Featured

Tharimmune Acquires Global Exclusive License to Develop INT-023, an Oral Anti-TNFα mAb for Treatment of Autoimmune Diseases

May 28, 2024 | Featured

Bio-Sourcing, Ciloa and Intract Pharma launch €3.4M EU project in inflammatory indications with €1.9M subsidies from EUREKA Eurostars

November 08, 2022 | Featured

Intract Announces Publication on Pre-clinical Data with Merck & Co. on Colon Targeted Delivery of JAK Inhibitor using Phloral® Technology

September 16, 2022 | Featured

Elasmogen and Intract Enter License Agreement for Soteria® and Phloral® Technologies

April 01, 2022 | Featured

Intract Pharma Appoints Dr Vipul Yadav as Chief Executive Officer

September 27, 2021 | Featured

Bio-Thera Solutions and Intract Pharma Enter Global Collaboration and License Agreement for Soteria® and Phloral® Drug Delivery Technologies to Enable Development of Oral Antibody Medicines

Page: 1 2 3 4 >

Copyright © 2018 Intract Pharma

A site by: Web Design London